Department of Urology, Medical Research Institute, Ninewells hospital and Medical School, Dundee, UK.
BJU Int. 2012 Nov;110(10):1426-35. doi: 10.1111/j.1464-410X.2012.11341.x. Epub 2012 Jul 3.
Surgical management of upper urinary tract transitional cell carcinoma (UUT-TCC) has significantly changed over the past two decades. Data for several new surgical techniques, including nephron-sparing surgery (NSS), is emerging. The study systematically reviewed the literature comparing (randomised and observational studies) surgical and oncological outcomes for various surgical techniques MEDLINE, EMBASE, Cochrane Library, CINAHL, British Nursing Index, AMED, LILACS, Web of Science, Scopus, Biosis, TRIP, Biomed Central, Dissertation Abstracts, ISI proceedings, and PubMed were searched to identify suitable studies. Data were extracted from each identified paper independently by two reviewers (B.R. and B.S.) and cross checked by a senior member of the team. The data analysis was performed using the Cochrane software Review manager version 5. Comparable data from each study was combined in a meta-analysis where possible. For dichotomous data, odds ratios with 95% confidence intervals (CIs) were estimated based on the fixed-effects model and according to an intention-to-treat analysis. If the data available were deemed not suitable for a meta-analysis it was described in a narrative fashion. One randomised control trial (RCT) and 19 observational studies comparing open nephroureterectomy (ONU) and laparoscopic NU (LNU) were identified. The RCT reported the LNU group to have statistically significantly less blood loss (104 vs 430 mL, P < 0.001) and mean time to discharge (2.30 vs 3.65 days, P < 0.001) than the ONU group. At a median follow-up of 44 months, the overall 5-year cancer-specific survival (CSS; 89.9 vs 79.8%) and 5-year metastasis-free survival rates (77.4 vs 72.5%) for the ONU were better than for LNU, respectively, although not statistically significant. A meta-analysis of the observational studies favoured LNU group for lower urinary recurrence (P < 0.001) and distant metastasis. The meta-analyses for local recurrence for the two groups were comparable. One retrospective study comparing ONU with a percutaneous approach for grade 2 disease reported no significant differences in CSS rates (53.8 vs 53.3 months). Three retrospective studies compared NSS and radical NU, and reported no significant differences in overall CSS and recurrence-free survival between the two approaches. Five retrospective studies compared various techniques of en bloc excision of the lower ureter. No technique was reported to be better (operative and oncological) than any other. This review concludes that there is a paucity of good quality evidence for the various surgical approaches for UUT-TCC. The techniques have been assessed and reported in many retrospective single-centre studies favouring LNU for better perioperative outcomes and comparable oncological safety. The reported observational studies data is further supported by one RCT.
过去二十年来,上尿路移行细胞癌(UUT-TCC)的外科治疗发生了重大变化。目前正在出现几种新的手术技术的数据,包括保留肾单位手术(NSS)。本研究系统地回顾了文献,比较了各种手术技术的外科和肿瘤学结果(随机和观察性研究),使用 MEDLINE、EMBASE、Cochrane 图书馆、CINAHL、英国护理索引、AMED、LILACS、Web of Science、Scopus、Biosis、TRIP、Biomed Central、论文摘要、ISI 会议和 PubMed 搜索了合适的研究。由两名评审员(BR 和 BS)独立从每篇确定的论文中提取数据,并由团队的一名高级成员进行交叉核对。数据分析使用 Cochrane 软件 Review manager 版本 5 进行。如果可能,将每个研究的可比数据合并到荟萃分析中。对于二项数据,根据固定效应模型和意向治疗分析,使用比值比和 95%置信区间(CI)进行估计。如果认为可用数据不适合进行荟萃分析,则以叙述方式进行描述。确定了一项随机对照试验(RCT)和 19 项比较开放肾输尿管切除术(ONU)和腹腔镜 NU(LNU)的观察性研究。RCT 报告 LNU 组的失血量明显少于 ONU 组(104 比 430 mL,P < 0.001),平均出院时间也明显短于 ONU 组(2.30 比 3.65 天,P < 0.001)。在中位数为 44 个月的随访中,ONU 的整体 5 年癌症特异性生存率(CSS;89.9%比 79.8%)和 5 年无转移生存率(77.4%比 72.5%)分别优于 LNU,尽管无统计学意义。对观察性研究的荟萃分析表明,LNU 组的下尿路复发率较低(P < 0.001)和远处转移率较低。两组局部复发的荟萃分析结果相似。一项比较 2 级疾病的 ONU 与经皮方法的回顾性研究报告称,CSS 率无显著差异(53.8 比 53.3 个月)。三项回顾性研究比较了 NSS 和根治性 NU,报告两种方法的总体 CSS 和无复发生存率无显著差异。五项回顾性研究比较了下段输尿管整块切除的各种技术。没有一种技术被报道比其他技术更好(手术和肿瘤学)。本综述得出的结论是,UUT-TCC 的各种手术方法缺乏高质量的证据。这些技术已经在许多回顾性单中心研究中进行了评估和报告,腹腔镜 NU 有利于围手术期结局,并且肿瘤学安全性相当。一项 RCT 进一步支持了报告的观察性研究数据。
Cochrane Database Syst Rev. 2011-4-13
J Laparoendosc Adv Surg Tech A. 2018-6
Cochrane Database Syst Rev. 2020-1-9
Cochrane Database Syst Rev. 2017-12-22
Cochrane Database Syst Rev. 2016-1-5
Cochrane Database Syst Rev. 2018-2-6
Cochrane Database Syst Rev. 2021-4-19
Curr Urol Rep. 2021-10-7
Transl Androl Urol. 2020-8
Robot Surg. 2016-7-4